Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac

Table 5

Renal safety of celecoxib and etoricoxib compared with diclofenac in patients with OA and RA in randomized controlled trials.

	Reference	Study duration	Celecoxib	Diclofenac	Etoricoxib
Hypertension
Hypertension, n (%)	White et al, 2002 [59]	Minimum 6 months	109 (2.7)	52 (2.6)
Discontinued due to any hypertension-related AEs, %	Whelton et al, 2006 [79]	Minimum 6 months	0.3	0.2
Incidence of hypertension-related AEs, n (%)	Krueger et al, 2008 [37]	Mean ~19 months		313 (15.2)	397 (19.5)
Discontinued due to any hypertension-related AEs, n (%)	Baraf et al, 2007 [36]	Mean ~9 months		23 (0.7)	81 (2.3)
Edema
Edema-related AEs, %	Whelton et al, 2006 [79]	Minimum 6 months	4.1	4.1
Incidence of edema-related AEs, n (%)	Krueger et al, 2008 [37]	Mean ~19 months		94 (4.6)	132 (6.5)
Renal
Discontinuations due to renal dysfunction, %	Cannon et al, 2006 [57]	Mean ~18 months		0.8	0.8

New-onset and aggravated pre-existing.
For ibuprofen (800 mg TID) 4.2%, p < 0.05 versus celecoxib.
OA cohort etoricoxib 60 mg.
p ≤ 0.05.
OA, osteoarthritis; RA, rheumatoid arthritis; AEs, adverse events.